Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial.

Skolarus TA, Metreger T, Hwang S, Kim HM, Grubb RL 3rd, Gingrich JR, Hawley ST.

Trials. 2017 Apr 18;18(1):181. doi: 10.1186/s13063-017-1925-4.


Presentation, management, and outcomes of complications following prostate cancer therapy.

Zaid UB, McAninch JW, Glass AS, Cinman NM, Breyer BN.

Transl Androl Urol. 2014 Jun;3(2):150-5. doi: 10.3978/j.issn.2223-4683.2014.04.05.


Integrative review on the non-invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies.

Faithfull S, Lemanska A, Aslet P, Bhatt N, Coe J, Drudge-Coates L, Feneley M, Glynn-Jones R, Kirby M, Langley S, McNicholas T, Newman J, Smith CC, Sahai A, Trueman E, Payne H.

Int J Clin Pract. 2015 Oct;69(10):1184-208. doi: 10.1111/ijcp.12693. Epub 2015 Aug 20. Review.


Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.

Contreras JA, Wilder RB, Mellon EA, Strom TJ, Fernandez DC, Biagioli MC.

Int Braz J Urol. 2015 Jan-Feb;41(1):40-5. doi: 10.1590/S1677-5538.IBJU.2015.01.07.


The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study.

Eisemann N, Nolte S, Schnoor M, Katalinic A, Rohde V, Waldmann A.

BMC Urol. 2015 Apr 10;15:28. doi: 10.1186/s12894-015-0025-6.


Improving couples' quality of life through a Web-based prostate cancer education intervention.

Song L, Rini C, Deal AM, Nielsen ME, Chang H, Kinneer P, Teal R, Johnson DC, Dunn MW, Mark B, Palmer MH.

Oncol Nurs Forum. 2015 Mar;42(2):183-92. doi: 10.1188/15.ONF.183-192.


Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Chen RC, Chang P, Vetter RJ, Lukka H, Stokes WA, Sanda MG, Watkins-Bruner D, Reeve BB, Sandler HM.

J Natl Cancer Inst. 2014 Jul 8;106(7). pii: dju132. doi: 10.1093/jnci/dju132. Print 2014 Jul. Review.


Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study.

Selli C, Bjartell A, Burgos J, Somerville M, Palacios JM, Benjamin L, Black L, Castro R.

Prostate Cancer. 2014;2014:472949. doi: 10.1155/2014/472949. Epub 2014 Mar 13.


Quality of Life and Sexual Health in the Aging of PCa Survivors.

Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S.

Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592. Epub 2014 Mar 17. Review. Erratum in: Int J Endocrinol. 2015;2015:675101.


Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment.

Storås AH, Sanda MG, Ferrer M, Loge JH, Dahl AA, Steinsvik EA, Guedea F, Cvancarova M, Fosså SD.

Clin Genitourin Cancer. 2014 Aug;12(4):e117-25. doi: 10.1016/j.clgc.2013.12.007. Epub 2014 Jan 3.


Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.

Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL.

Can Urol Assoc J. 2013 Nov;7(11-12):463-70. doi: 10.5489/cuaj.1482. Review.


Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.

Rodrigues G, Yao X, Loblaw DA, Brundage M, Chin JL; Genitourinary Cancer Disease Site Group.

Can Urol Assoc J. 2013 May-Jun;7(5-6):E411-6. doi: 10.5489/cuaj.478.


Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options.

Skowronek J.

J Contemp Brachytherapy. 2013 Mar;5(1):33-41. doi: 10.5114/jcb.2013.34342. Epub 2013 Mar 29.


Quality of life after prostate cancer treatments in patients comparable at baseline.

van Tol-Geerdink JJ, Leer JW, van Oort IM, van Lin EJ, Weijerman PC, Vergunst H, Witjes JA, Stalmeier PF.

Br J Cancer. 2013 May 14;108(9):1784-9. doi: 10.1038/bjc.2013.181. Epub 2013 Apr 23.


Prospective evaluation of quality of life 54 months after high-dose intensity-modulated radiotherapy for localized prostate cancer.

Goineau A, Marchand V, Rigaud J, Bourdin S, Rio E, Campion L, Bonnaud-Antignac A, Mahé MA, Supiot S.

Radiat Oncol. 2013 Mar 6;8:53. doi: 10.1186/1748-717X-8-53.


Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA.

Cancer. 2013 May 1;119(9):1729-35. doi: 10.1002/cncr.27956. Epub 2013 Feb 22.


Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.

Katz A, Ferrer M, Suárez JF; Multicentric Spanish Group of Clinically Localized Prostate Cancer.

Radiat Oncol. 2012 Nov 20;7:194. doi: 10.1186/1748-717X-7-194.


High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer.

Challapalli A, Jones E, Harvey C, Hellawell GO, Mangar SA.

Br J Radiol. 2012 Nov;85 Spec No 1:S18-27. doi: 10.1259/bjr/15403217. Review.


Validity testing of the stopwatch urine stream interruption test in radical prostatectomy patients.

Robinson JP, Burrell SA, Avi-Itzhak T, McCorkle R.

J Wound Ostomy Continence Nurs. 2012 Sep-Oct;39(5):545-51.

Supplemental Content

Support Center